MARKET

PROK

PROK

ProKidney
NASDAQ
1.020
+0.030
+3.01%
After Hours: 1.010 -0.01 -0.98% 18:25 04/25 EDT
OPEN
1.000
PREV CLOSE
0.9902
HIGH
1.030
LOW
0.9440
VOLUME
847.59K
TURNOVER
--
52 WEEK HIGH
4.440
52 WEEK LOW
0.4603
MARKET CAP
298.55M
P/E (TTM)
-1.6323
1D
5D
1M
3M
1Y
5Y
1D
Major Investment Alert: Carso De-C Inmobiliaria Acquires ProKidney Shares!
TipRanks · 2d ago
Major Investment Alert: ProKidney Stock Sees New Stakeholder!
TipRanks · 5d ago
Weekly Report: what happened at PROK last week (0414-0418)?
Weekly Report · 5d ago
Major Investment Alert: ProKidney Stock Acquisition!
TipRanks · 04/19 02:01
Major Investment Alert: ProKidney Stock Sees Significant Purchase!
TipRanks · 04/17 02:03
Major Investment Alert: ProKidney Stock Sees Big Buy-In!
TipRanks · 04/15 02:01
Weekly Report: what happened at PROK last week (0407-0411)?
Weekly Report · 04/14 10:51
Weekly Report: what happened at PROK last week (0331-0404)?
Weekly Report · 04/07 10:50
More
About PROK
More
ProKidney Corp. is a clinical-stage cellular therapeutics company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, rilparencel, is designed to preserve kidney function in a CKD patient’s diseased kidneys. Rilparencel is a product that includes autologous selected renal cells (SRCs) prepared from a patient’s own (autologous) kidney cells. Rilparencel is an investigational product that includes a mixture of kidney cells prepared from the participant’s own kidney tissue. The SRC are formulated rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure that is repeatable, if necessary. It is conducting a global Phase III development program and multiple Phase II clinical trials for rilparencel in subjects with moderate to severe CKD and diabetes.
Recently
Symbol
Price
%Change

Webull offers ProKidney Corp stock information, including NASDAQ: PROK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PROK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PROK stock methods without spending real money on the virtual paper trading platform.